APRIL

Home
Ligands
APRIL (Human)

GtoPdb Ligand ID: 5068

Compound class: Endogenous peptide in human, mouse or rat

Comment: APRIL (also known as tumor necrosis factor ligand superfamily member 13; TNFSF13) is a protein of the TNF superfamily recognized by the cell surface catalytic receptor TACI [9] and other TNF family receptors [3]. Three APRIL isoforms have bee reported [1]. We provide the amino acid sequence for the mature peptide chain (i.e. without the 104 amino acid propeptide leader sequence which is cleaved by furin convertase in the Golgi apparatus prior to secretion [4]).

Species: Human

References
1. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, Siegrist CA. (2008) APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood, 111 (5): 2755-64. [PMID:18180376]
2. Cogollo E, Cogollo E, Silva MA, Isenberg D. (2015) Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther, 9: 1331-9. [PMID:25834391]
3. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE et al.. (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med, 188 (6): 1185-90. [PMID:9743536]
4. López-Fraga M, Fernández R, Albar JP, Hahne M. (2001) Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep, 2 (10): 945-51. [PMID:11571266]
5. Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z et al.. (2019) A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int, 96 (1): 104-116. [PMID:31027890]
6. Samy E, Wax S, Huard B, Hess H, Schneider P. (2017) Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol, 36 (1): 3-19. [PMID:28215100]
7. Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. (2021) Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol, 43 (6): 666-673. [PMID:34519594]
8. Van Eenennaam H, Van Elsas A, Hulsik DL, Medema JP. (2018) Altered APRIL binding antibodies. Patent number: US9969808B2. Assignee: Aduro Biotech Holdings. Priority date: 09/01/2015. Publication date: 15/05/2018.
9. Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E et al.. (2000) Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem, 275 (45): 35478-85. [PMID:10956646]

References

1. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, Siegrist CA. (2008)
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.
Blood, 111 (5): 2755-64. [PMID:18180376]

2. Cogollo E, Cogollo E, Silva MA, Isenberg D. (2015)
Profile of atacicept and its potential in the treatment of systemic lupus erythematosus.
Drug Des Devel Ther, 9: 1331-9. [PMID:25834391]

3. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE et al.. (1998)
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth.
J Exp Med, 188 (6): 1185-90. [PMID:9743536]

4. López-Fraga M, Fernández R, Albar JP, Hahne M. (2001)
Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase.
EMBO Rep, 2 (10): 945-51. [PMID:11571266]

5. Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z et al.. (2019)
A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy.
Kidney Int, 96 (1): 104-116. [PMID:31027890]

6. Samy E, Wax S, Huard B, Hess H, Schneider P. (2017)
Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
Int Rev Immunol, 36 (1): 3-19. [PMID:28215100]

7. Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. (2021)
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Immunopharmacol Immunotoxicol, 43 (6): 666-673. [PMID:34519594]

8. Van Eenennaam H, Van Elsas A, Hulsik DL, Medema JP. (2018)
Altered APRIL binding antibodies.
Patent number: US9969808B2. Assignee: Aduro Biotech Holdings. Priority date: 09/01/2015. Publication date: 15/05/2018.

9. Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E et al.. (2000)
Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS.
J Biol Chem, 275 (45): 35478-85. [PMID:10956646]